Professor Rena M. Conti is a distinguished scholar in health economics and public policy, renowned for her influential contributions to the economics of healthcare markets, pharmaceutical innovation, and drug pricing regulation. With 156 scholarly publications, over 4,890 citations, and an h-index of 31, she has established herself as a global authority in the intersection of healthcare policy, economic analysis, and market dynamics. Her research focuses on understanding the mechanisms driving biopharmaceutical pricing, access to essential medicines, and the sustainability of healthcare systems. Professor Conti’s work has been featured in leading international journals, including JAMA, Health Affairs, and Nature Biotechnology, where her empirical analyses have informed both academic discourse and practical policymaking. Her collaborations extend across academia, government, and industry, where she has worked with public health agencies, pharmaceutical firms, and think tanks to design evidence-based policies that promote innovation while ensuring patient affordability. A key aspect of her impact lies in her ability to bridge the gap between economic modeling and real-world policy implementation, offering pragmatic solutions for optimizing market efficiency and health outcomes. She has also been actively involved in mentoring young researchers and contributing to interdisciplinary initiatives that explore the ethical, economic, and regulatory dimensions of healthcare innovation. Her leadership in shaping policy frameworks related to biosimilars, value-based pricing, and healthcare equity has positioned her as a leading voice in advancing sustainable global health systems. Beyond academia, her work has contributed to public debates on balancing innovation incentives with affordability, influencing policymakers and industry leaders worldwide. Through her rigorous scholarship, collaborative outlook, and commitment to public health, Professor Conti continues to play a pivotal role in transforming the global conversation on healthcare economics, ensuring that economic research serves both scientific advancement and social equity.

Profile: Scopus | ORCID | Google Scholar

Featured Publications

Qato, D. M., Alexander, G. C., Conti, R. M., Johnson, M., Schumm, P., & Lindau, S. T. (2008). Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA, 300(24), 2867–2878.

Epstein, A. M., Ayanian, J. Z., Keogh, J. H., Noonan, S. J., Armistead, N., Cleary, P. D., … (et al.) (2000). Racial disparities in access to renal transplantation—clinically appropriate or due to underuse or overuse? New England Journal of Medicine, 343(21), 1537–1544.

Howard, D. H., Bach, P. B., Berndt, E. R., & Conti, R. M. (2015). Pricing in the market for anticancer drugs. Journal of Economic Perspectives, 29(1), 139–162.

Dorsey, E. R., Rabbani, A., Gallagher, S. A., Conti, R. M., & Alexander, G. C. (2010). Impact of FDA black box advisory on antipsychotic medication use. Archives of Internal Medicine, 170(1), 96–103.

Dusetzina, S. B., Higashi, A. S., Dorsey, E. R., Conti, R., Huskamp, H. A., Zhu, S., … (et al.) (2012). Impact of FDA drug risk communications on health care utilization and health behaviors: A systematic review. Medical Care, 50(6), 466–478.